Premium
Cholinergic therapy in dementia
Author(s) -
Whitehouse P. J.
Publication year - 1993
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1993.tb04254.x
Subject(s) - tacrine , cholinergic , dementia , medicine , cholinesterase , disease , alzheimer's disease , neuroscience , galantamine , nicotinic agonist , muscarinic acetylcholine receptor , pharmacology , acetylcholinesterase , psychology , donepezil , receptor , biology , biochemistry , enzyme
After reviewing the evidence for cholinergic pathology in Alzheimer's disease and related disorders, this paper reviews strategies for treating dementia using cholinomimetic drugs. Special attention is paid to cholinesterase inhibitors, particularly tacrine, the drug recently approved by the FDA. New studies suggesting that muscarinic and nicotinic cholinergic receptor active drugs may be more effective will be reviewed. Brief mention will be made of strategies to slow the progression of Alzheimer's disease.